Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alphabet Inc.GOOGL · Entity 2516 | Director | September 14, 2026 | September 17, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP, CFO | February 12, 2019 | March 14, 2019 |
| HONEYWELL INTERNATIONAL INC- · Entity 2988 | Director | February 18, 2025 | February 20, 2025 |
| Salesforce, Inc.CRM · Entity 2842 | Director · President and COFO | September 22, 2026 | September 23, 2026 |
| Vertiv Holdings CoVRT · Entity 440 | Director | November 19, 2024 | November 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alphabet Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class C Google Stock UnitsSEC Table I · non-derivative | Direct | 941 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 1 · Balance 941 F1: The Google Stock Units (GSUs) entitle the Reporting Person to receive one share of Alphabet Inc. Class C Capital Stock for each share underlying the GSU as GSU vests. 1/48 of GSUs shall vest on the 25th of the month of the Grant Date, vesting 1/48 every 1 month(s) for 7 event(s); 1/48 of GSUs shall vest on the 1st of the month 7 month(s) after the Grant Date, vesting 1/48 every 1 month(s) for 41 event(s), subject to continued employment on such vesting date(s). F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F3: Consists of 1 DEUs and 940 GSUs. |
| Class C Google Stock UnitsSEC Table I · non-derivative | Direct | 597 |
Reported balance
After 2026-09-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-14 · Grant · Acquired 0.4 · Balance 597 F4: 1/48th of GSUs vested on July 25, 2023 and an additional 1/48th of GSUs will vest monthly thereafter until the GSUs are fully vested, subject to continued service on such vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F5: Consists of 5 DEUs and 592 GSUs. |
| Class C Google Stock UnitsSEC Table I · non-derivative | Direct | 903 |
Reported balance
After 2026-09-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-14 · Grant · Acquired 1 · Balance 903 F6: 1/48 of GSUs vests on the 25th day of each month following the grant date for 31 months and on the 1st day of each month for the following 17 months, subject to continued employment on such vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F7: Consists of 7 DEUs and 896 GSUs. |
| Class C Google Stock UnitsSEC Table I · non-derivative | Direct | 1,433 |
Reported balance
After 2026-09-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-14 · Grant · Acquired 1 · Balance 1,433 F8: 1/48 of GSUs will vest on the 25th day of each month following the grant date for 19 months and on the 1st day of each month for the following 29 months, subject to continued service on the Board on the applicable vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F9: Consists of 5 DEUs and 1,428 GSUs. |
| Class C Capital StockSEC Table I · non-derivative | Direct | 32,559 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 32,559 |
Filing footnotes · ownership attribution and instrument terms
F1: The Google Stock Units (GSUs) entitle the Reporting Person to receive one share of Alphabet Inc. Class C Capital Stock for each share underlying the GSU as GSU vests. 1/48 of GSUs shall vest on the 25th of the month of the Grant Date, vesting 1/48 every 1 month(s) for 7 event(s); 1/48 of GSUs shall vest on the 1st of the month 7 month(s) after the Grant Date, vesting 1/48 every 1 month(s) for 41 event(s), subject to continued employment on such vesting date(s).
F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests.
F3: Consists of 1 DEUs and 940 GSUs.
F4: 1/48th of GSUs vested on July 25, 2023 and an additional 1/48th of GSUs will vest monthly thereafter until the GSUs are fully vested, subject to continued service on such vesting dates.
F5: Consists of 5 DEUs and 592 GSUs.
F6: 1/48 of GSUs vests on the 25th day of each month following the grant date for 31 months and on the 1st day of each month for the following 17 months, subject to continued employment on such vesting dates.
F7: Consists of 7 DEUs and 896 GSUs.
F8: 1/48 of GSUs will vest on the 25th day of each month following the grant date for 19 months and on the 1st day of each month for the following 29 months, subject to continued service on the Board on the applicable vesting dates.
F9: Consists of 5 DEUs and 1,428 GSUs.
GILEAD SCIENCES, INC.
Report date February 12, 2019 · Filed March 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,620 |
Ending reported balance
After 2019-02-25 transaction · row 4
3 source rows · reconciled sequenceRow 1 · 2019-02-12 · Other · Disposed 11,588 · Balance 21,620 F1: Shares transferred to family trust. Row 3 · 2019-02-15 · Grant · Acquired 330 · Balance 21,950 F2: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2018 through February 15, 2019. This transaction is exempt under Rule 16b-3(c). F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2019. Row 4 · 2019-02-25 · Other · Disposed 330 · Balance 21,620 F1: Shares transferred to family trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 116,993 |
Reported balance
After 2019-02-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-02-12 · Other · Acquired 11,588 · Balance 116,993 F1: Shares transferred to family trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 117,323 |
Reported balance
After 2019-02-25 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2019-02-25 · Other · Acquired 330 · Balance 117,323 F1: Shares transferred to family trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares transferred to family trust.
F2: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2018 through February 15, 2019. This transaction is exempt under Rule 16b-3(c).
F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2019.
HONEYWELL INTERNATIONAL INC
Report date February 18, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,041 |
Ending reported balance
After 2025-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-18 · Exercise / conversion · Acquired 3,164 · Balance 3,165 F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018. Row 2 · 2025-02-18 · Tax withholding · Disposed 2,124 · Balance 1,041 |
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.92 · Expires 2025-04-26 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-18 · Exercise / conversion · Disposed 3,164 · Balance 0 F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018. F2: Represents exempt grant of non-qualified stock options under the 2006 Stock Plan for Non-Employee Directors that vest in four equal annual installments, with the first installment vesting on April 1, 2016. |
| Common StockSEC Table I · non-derivative | IndirectHeld in a trust | 12,132 |
Reported balance
Holding disclosure · report date 2025-02-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 12,132 |
Filing footnotes · ownership attribution and instrument terms
F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018.
F2: Represents exempt grant of non-qualified stock options under the 2006 Stock Plan for Non-Employee Directors that vest in four equal annual installments, with the first installment vesting on April 1, 2016.
Salesforce, Inc.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,750 |
Ending reported balance
After 2026-09-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-22 · Exercise / conversion · Acquired 1,831 · Balance 50,658 Row 2 · 2026-09-22 · Tax withholding · Disposed 908 · Balance 49,750 F1: Represents shares withheld to satisfy the reporting person's tax liability upon vesting and settlement of a restricted stock unit award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-22 | Direct | 18,310 |
Reported balance
After 2026-09-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-22 · Exercise / conversion · Disposed 1,831 · Balance 18,310 F2: Restricted Stock Units convert to shares of common stock on a one-for-one basis. F3: These restricted stock units vest as to 25% of the original grant on March 22, 2026 and vest as to 1/16 of the original grant quarterly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy the reporting person's tax liability upon vesting and settlement of a restricted stock unit award.
F2: Restricted Stock Units convert to shares of common stock on a one-for-one basis.
F3: These restricted stock units vest as to 25% of the original grant on March 22, 2026 and vest as to 1/16 of the original grant quarterly thereafter.
Vertiv Holdings Co
Report date November 19, 2024 · Filed November 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,000 |
Last balance in matching sequence
After 2024-11-19 transaction · row 9
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
9 source rowsRow 1 · 2024-11-19 · Sale · Disposed 14 · Balance 9,986 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 2 · 2024-11-19 · Sale · Disposed 650 · Balance 9,336 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F3: The trade was executed in a series of transactions with a price range of $127.94 to $128.35, inclusive, with a weighted average price of $128.1338. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 3 · 2024-11-19 · Sale · Disposed 327 · Balance 9,009 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F4: The trade was executed in a series of transactions with a price range of $129.98 to $130.51, inclusive, with a weighted average price of $130.3515. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 4 · 2024-11-19 · Sale · Disposed 343 · Balance 8,666 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F5: The trade was executed in a series of transactions with a price range of $132.50 to $132.70, inclusive, with a weighted average price of $132.6176. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 5 · 2024-11-19 · Sale · Disposed 683 · Balance 7,983 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F6: The trade was executed in a series of transactions with a price range of $133.915 to $134.56, inclusive, with a weighted average price of $134.0396. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 6 · 2024-11-19 · Sale · Disposed 883 · Balance 7,100 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F7: The trade was executed in a series of transactions with a price range of $134.995 to $135.89, inclusive, with a weighted average price of $135.4847. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 7 · 2024-11-19 · Sale · Disposed 701 · Balance 6,399 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F8: The trade was executed in a series of transactions with a price range of $136.08 to $136.94, inclusive, with a weighted average price of $136.5568. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 8 · 2024-11-19 · Sale · Disposed 703 · Balance 5,696 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F9: The trade was executed in a series of transactions with a price range of $137.24 to $138.065, inclusive, with a weighted average price of $137.7667. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 9 · 2024-11-19 · Sale · Disposed 696 · Balance 5,000 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F10: The trade was executed in a series of transactions with a price range of $138.475 to $138.92, inclusive, with a weighted average price of $138.7824. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024.
F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust.
F3: The trade was executed in a series of transactions with a price range of $127.94 to $128.35, inclusive, with a weighted average price of $128.1338. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The trade was executed in a series of transactions with a price range of $129.98 to $130.51, inclusive, with a weighted average price of $130.3515. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: The trade was executed in a series of transactions with a price range of $132.50 to $132.70, inclusive, with a weighted average price of $132.6176. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6: The trade was executed in a series of transactions with a price range of $133.915 to $134.56, inclusive, with a weighted average price of $134.0396. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F7: The trade was executed in a series of transactions with a price range of $134.995 to $135.89, inclusive, with a weighted average price of $135.4847. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F8: The trade was executed in a series of transactions with a price range of $136.08 to $136.94, inclusive, with a weighted average price of $136.5568. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F9: The trade was executed in a series of transactions with a price range of $137.24 to $138.065, inclusive, with a weighted average price of $137.7667. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F10: The trade was executed in a series of transactions with a price range of $138.475 to $138.92, inclusive, with a weighted average price of $138.7824. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalyst Partners Acquisition Corp.
Report date February 07, 2023 · Filed February 10, 2023
Section 16 reporting ended · disclosed 2023-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-07 · Other · Disposed 37,000 · Balance 0 F1: On January 31, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on February 7, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 31, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on February 7, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,800 | $78.76 | $378,048.00 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 6 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,082 Read SEC document |
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,710 | $79.39 | $691,474.71 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 5 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,882 F5 · price: Sale prices reported for the transactions reported here range from $78.88 to $79.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,840 | $78.61 | $223,258.93 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 4 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,592 F4 · price: Sale prices reported for the transactions reported here range from $77.85 to $78.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,250 | $24.30 | $273,318.75 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,800 | $23.76 | $114,024.00 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2014 Filed May 5, 2014 23:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,550 | $19.09 | $220,431.75 |
DisclosureSEC source: 0001179110-14-007665 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 36,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-006695 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 63,600 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| March 17, 2014 Filed Apr 10, 2014 18:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 36,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-006695 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,832 Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 40,180 | $79.92 | $3,211,185.60 |
DisclosureSEC source: 0001179110-14-004893 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,652 Read SEC document |
| March 06, 2014 Filed Mar 10, 2014 20:11 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-004893 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,832 F1 · shares: Vesting of performance share awards on March 6, 2014 Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · derivative · entry 12 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 3,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · derivative · entry 11 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 11,250 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,800 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · derivative · entry 10 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 4,800 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,550 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · derivative · entry 9 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 Underlying: Common Stock · 11,550 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,846 | $84.05 | $743,496.57 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 7 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,832 F6 · price: Sale prices reported for the transactions reported here range from $83.97 to $84.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 19,276 | $83.63 | $1,612,009.47 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 6 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,678 F5 · price: Sale prices reported for the transactions reported here range from $82.96 to $83.96. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,478 | $82.38 | $204,128.97 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 5 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,954 F4 · price: Sale prices reported for the transactions reported here range from $81.93 to $82.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,250 | $24.30 | $273,318.75 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 4 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,550 | $19.09 | $220,431.75 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,800 | $23.76 | $114,024.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $24.91 | $74,715.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2014 Filed Mar 5, 2014 02:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-004422 · edgar.xml · nonDerivative · entry 8 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 26,780 F7 · kind: Shares gifted to an endowment. Read SEC document |
| February 25, 2014 Filed Feb 25, 2014 22:47 UTC | Salesforce, Inc. CRM · Entity 2842 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-008388 · form4.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 F1 · price: Shares awarded from the Issuer's 2013 Equity Incentive Plan for board service. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001179110-14-003582 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $83.24 | $416,217.50 |
DisclosureSEC source: 0001179110-14-003582 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,832 F3 · price: Sale prices reported for the transactions reported here range from $82.87 to $83.57. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $23.60 | $118,000.00 |
DisclosureSEC source: 0001179110-14-003582 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2014 Filed Feb 21, 2014 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 968 | $83.36 | $80,692.48 |
DisclosureSEC source: 0001179110-14-003319 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,832 F2 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: Sale prices reported for the transactions reported here range from $82.87 to $83.74. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 14, 2014 Filed Feb 21, 2014 20:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 968 | $21.94 | $21,242.66 |
DisclosureSEC source: 0001179110-14-003319 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,800 F1 · shares: 968 shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,460 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001179110-14-001947 · edgar.xml · derivative · entry 2 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,280 Underlying: Common Stock · 15,460 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 44,820 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001179110-14-001947 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,820 Underlying: Common Stock · 44,820 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 9,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001419 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,832 F2 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on February 1, 2013. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2015. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001419 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $24.91 | $0.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · derivative · entry 11 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 3,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · derivative · entry 10 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Underlying: Common Stock · 11,250 shares Expires 2022-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,800 | $0.00 Strike: $23.76 | $0.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · derivative · entry 9 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 4,800 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · derivative · entry 8 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,550 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · derivative · entry 7 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 11,550 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 35,600 | $75.03 | $2,671,213.96 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 6 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: Sale prices reported for the transactions reported here range from $74.44 to $75.43. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $24.91 | $74,715.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 5 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,800 | $23.76 | $114,024.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 4 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,250 | $24.30 | $273,318.75 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,000 | $23.60 | $118,000.00 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,550 | $19.09 | $220,431.75 |
DisclosureSEC source: 0001179110-14-000528 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2013 Filed Nov 29, 2013 18:34 UTC | Salesforce, Inc. CRM · Entity 2842 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-033192 · form4.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · price: Shares awarded from the Issuer's 2013 Equity Incentive Plan for board service. Read SEC document |
| November 14, 2013 Filed Dec 10, 2013 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 22,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-017681 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 27,130 F1 · kind: Shares gifted to family trust. Read SEC document |
| November 14, 2013 Filed Dec 10, 2013 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 22,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-017681 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares gifted to family trust. Read SEC document |
| November 06, 2013 Filed Nov 8, 2013 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $69.70 | $6,970.00 |
DisclosureSEC source: 0001179110-13-016352 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,826 F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 06, 2013 Filed Nov 8, 2013 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $69.17 | $76,085.02 |
DisclosureSEC source: 0001179110-13-016352 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,926 F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3 · price: Sale prices reported for the transactions reported here range from $68.66 to $69.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 06, 2013 Filed Nov 8, 2013 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,669 | $68.22 | $113,854.84 |
DisclosureSEC source: 0001179110-13-016352 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,026 F1 · kind: The sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: Sale prices reported for the transactions reported here range from $67.65 to $68.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 05, 2013 Filed Nov 8, 2013 00:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-016312 · edgar.xml · derivative · entry 5 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 20% every year thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 20% every year thereafter until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.